Pharmacotherapy 1984-01-01

Piretanide: a loop-active diuretic. Pharmacology, therapeutic efficacy and adverse effects.

J D Marsh, T W Smith

Index: Pharmacotherapy 4(4) , 170-80, (1984)

Full Text: HTML

Abstract

Piretanide is a high-ceiling, loop-active diuretic that has been developed for treatment of congestive heart failure, hypertension and edematous states caused by renal and hepatic diseases. Piretanide is structurally related to furosemide and bumetanide; when administered orally, 6 mg of piretanide is as effective as 40 mg of furosemide, and when administered intravenously, 12 mg of piretanide is as effective as 40 mg of furosemide. Piretanide enhances water and sodium excretion in patients with congestive heart failure, with nephrotic syndrome and with cirrhosis and ascites. Adverse effects reported to date are limited to those attributable to excess loss of fluid and electrolytes. Under some conditions, piretanide appears to be less potassium wasting than thiazide diuretics or other loop-active diuretics.

Related Compounds

  • Piretanide

Related Articles:

Role of EDHF in the vasodilatory effect of loop diuretics in guinea-pig mesenteric resistance arteries.

2000-11-01

[Br. J. Pharmacol. 131(6) , 1211-9, (2000)]

Modulation of chloride, potassium and bicarbonate transport by muscarinic receptors in a human adenocarcinoma cell line.

1999-01-01

[Br. J. Pharmacol. 126(1) , 269-79, (1999)]

Fc epsilon RI-mediated chloride uptake by rat mast cells: modulation by chloride transport inhibitors in relation to histamine secretion.

1997-11-01

[Br. J. Pharmacol. 122(6) , 1188-94, (1997)]

Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial.

1993-09-15

[Am. J. Cardiol. 72(9) , 666-71, (1993)]

Increased (Na+K+Cl) cotransport in rat arterial smooth muscle in deoxycorticosterone (DOCA)/salt-induced hypertension.

1999-01-01

[J. Vasc. Res. 36(6) , 492-501, (1999)]

More Articles...